Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 13/20 | 0.42 |
| ▸ | APOB | P04114 | 7/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795163 | 0.92 | KMT2A (0.38) | MAPTSIRT1 | |
| SCHEMBL6491198 | 0.91 | APOB (0.39) | MTTPAPOBTP53MAPTRXFP1 | |
| SCHEMBL6794094 | 0.91 | CCR2 (0.39) | TP53SMOMAPTSIRT1 | |
| SCHEMBL6502663 | 0.91 | APOB (0.44) | MTTPAPOBTP53MAPTRXFP1 | |
| SCHEMBL6788744 | 0.91 | NPC1 (0.41) | MTTPTP53MAPTSIRT1 | |
| SCHEMBL6489412 | 0.89 | SMO (0.45) | MTTPAPOBSMO | |
| SCHEMBL6488574 | 0.88 | TP53 (0.45) | MTTPAPOBTP53SMOMAPT | |
| SCHEMBL6792697 | 0.87 | MTTP (0.45) | MTTPAPOBSMORXFP1 | |
| SCHEMBL6794499 | 0.87 | CYP3A4 (0.40) | MTTPTP53MAPTSIRT1 | |
| SCHEMBL6500248 | 0.86 | APOB (0.45) | MTTPAPOBTP53MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885APOB 1/4885TP53 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.